|

GT201 Clinical Trials

3 actively recruiting trials

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

  • Grit Biotechnology3

Indications

  • Cancer3
  • Solid Tumor2
  • Solid Tumor, Adult1

Other3 trials

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors
Phase 1
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
Phase 1/2
GT201 Injection For The Treatment Of Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.